Increase in direct social care costs of Alzheimer's disease in Japan depending on dementia severity

2019 ◽  
Vol 19 (10) ◽  
pp. 1023-1029 ◽  
Author(s):  
Hajime Takechi ◽  
Atsuko Kokuryu ◽  
Akira Kuzuya ◽  
Shinji Matsunaga
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Social Care ◽  
Dementia Severity ◽  
Care Costs

scholarly journals The Impact of Alzheimer’s Disease and Related Dementias on Dental Care Utilization and Costs in Older Adults

2020 ◽  
Vol 4 (Supplement_1) ◽  
pp. 800-800
Author(s):  
Sam Li ◽  
Isaac Donkor ◽  
Liang Hong ◽  
Kevin Lu ◽  
Bei Wu
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Dental Care ◽  
Negative Binomial ◽  
Self Report ◽  
Care Utilization ◽  
Limited Information ◽  
Dental Care Utilization ◽  
The Impact ◽  
Care Costs

Abstract There is limited information on the impact of cognition function on dental care utilization and costs. This study used the Medicare current beneficiaries survey in 2016 and included 4,268 participants 65+. Dental care utilization and costs were measured by self-report and included preventive and treatment events. Negative binomial regression and generalized linear regression were used to examine the impact of Alzheimer’s disease (AD) and related dementia (RD) on dental care utilization and costs. We found that AD was not associated with dental care utilization, but RD was associated with a lower number of total treatment dental care visits (IRR: 0.60; 95% CI: 0.37~0.98). RD was not associated with dental care costs, but AD was associated with higher total dental care costs (estimate: 1.08; 95% CI: 0.14~2.01) and higher out-of-pocket costs (estimate: 1.25; 95% CI: 0.17~2.32). AD and RD had different impacts on different types of dental care utilization and costs. Part of a symposium sponsored by the Oral Health Interest Group.

scholarly journals Voxel-based analysis of confounding effects of age and dementia severity on cerebral metabolism in Alzheimer's disease

2000 ◽  
Vol 10 (1) ◽  
pp. 39-48 ◽  
Author(s):  
Eric Salmon ◽  
Fabienne Collette ◽  
Christian Degueldre ◽  
Christian Lemaire ◽  
Georges Franck
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cerebral Metabolism ◽  
Dementia Severity

Serbia

2019 ◽  
pp. 251-256
Author(s):  
Slavica Djukic-Dejanovic ◽  
Gorica Djokic
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Care Programme ◽  
Governmental Organization ◽  
Support Programme ◽  
Home Help ◽  
People With Dementia ◽  
Neurology Clinic ◽  
Palliative Care Programme ◽  
Care Costs

Serbia is among the demographically older countries in the world, with 18% of the population aged above 65 years. One in two persons older than 65 years lives with an old spouse. The Serbian National Strategy on ageing identified poverty as a widespread companion of ageing, with a rising poverty index. In 2007, the first non-governmental organization, called ‘Alchajmer’, was established in Sremska Kamenica to support people with Alzheimer’s disease and their caregivers. In 2008, the first Centre for Memory Disorders and Dementia was established as part of the Neurology Clinic at the Clinical Centre of Serbia in Belgrade. A National Guide for Alzheimer’s disease was published in 2013. The Serbian health insurance scheme covers care costs for people with severe dementia through its support programme called Advanced Home Help, which includes provision of geriatric housekeepers from the palliative care programme, as well as modest financial support in accordance with the state’s financial capabilities. There are over 160,000 people with dementia in Serbia, comprising approximately 13% of the Serbian population aged above 65 years, of whom only 4% are prescribed appropriate pharmacological treatment.

The planning of appropriate medical and social care in dementia

2011 ◽  
Author(s):  
Marcel GM Olde-Rikkert ◽  
Irena Draskovic ◽  
Myrra Vernooij-Dassen
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Cognitive Reserve ◽  
Social Care ◽  
Evidence Base ◽  
Significant Decline ◽  
Simple Theory ◽  
Innovative Research ◽  
Research Questions ◽  
Clinically Significant

• Alzheimer’s disease is probably caused by multiple disease processes that occur simultaneously, have a long preclinical history, and together cause a clinically significant decline of cognitive reserve• The cognitive reserve theory is an attractive simple theory that may enable clinicians and researcher to formulate innovative research questions, however it still requires an evidence base...

scholarly journals Predictions of Alzheimer’s disease treatment and care costs in European countries

PLoS ONE ◽  
2019 ◽  
Vol 14 (1) ◽  
pp. e0210958 ◽  
Author(s):  
Richard Cimler ◽  
Petra Maresova ◽  
Jitka Kuhnova ◽  
Kamil Kuca
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
European Countries ◽  
Disease Treatment ◽  
Care Costs

scholarly journals 98 Use of Drgs with Anticholinergic Properties in People Living with Alzheimer’s Disease: Data from NILVAD

2019 ◽  
Vol 48 (Supplement_3) ◽  
pp. iii17-iii65
Author(s):  
Sean P Kennelly ◽  
Adam H Dyer ◽  
Claire Murphy ◽  
Brian Lawlor
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Prolonged Exposure ◽  
Anatomical Therapeutic Chemical ◽  
Community Dwelling ◽  
Disease Assessment ◽  
Anticholinergic Medication ◽  
Dementia Severity ◽  
Increased Risk ◽  
Anticholinergic Burden

Abstract Background Prolonged exposure to anticholinergic medication, particularly in midlife, is associated with increased risk of cognitive impairment/dementia. Less well explored is the ongoing use of drugs with anticholinergic properties in patients with Alzheimer’s Disease (AD), where the potential to accelerate cognitive decline may be greatest. Methods We analysed medication data from the NILVAD trial, a clinical trial examining the efficacy of Nilvadapine in mild-moderate Alzheimer’s Disease (AD). Drgs were coded based on their Anatomical Therapeutic Chemical (ATC) classification and Anticholinergic Burden Scale (ABS) applied to each participant’s medication list. Logistic and linear regression were used to model predictors of potential anticholinergic medication use/total ABS score. Results Of 510 participants with AD (mean age 72.8 +/-8.3 years; 62% female), just over one-quarter (N = 134, 26.27%) were prescribed a drug with potential/definite anticholinergic properties. Half of these had an anticholinergic burden score of 3 or greater (N = 67, 13.4%). The most frequent definite anticholinergics prescribed included quetiapine (N=27) oxybutynin (N = 22), paroxetine (N=14) and amitriptyline (N=8). Usage did not significantly differ by country or study arm. Overall, 88.43% of patients were prescribed a cholinesterase inhibitor. On multivariate analysis of potential/definite anticholinergic usage, age (p=0.044; OR 1.03, 1.01-1.06), total number of medications (p=0.001, OR 1.3, 1.18-1.41) as well as a greater dementia severity rated using the Alzheimer’s Disease Assessment Scale (ADAS-Cog) (p=0.008; 1.04 1.01-1.07) were associated with likelihood of anticholinergic use. Conclusion Over one-quarter of community-dwelling older patients with AD are prescribed a drug with potential or definite anticholinergic properties. Use of drugs with potential/definite anticholinergic properties were associated with total medication burden in addition to greater dementia severity at baseline. This is particularly pertinent given the deleterious cognitive effects of anticholinergic medication. Further attention to reducing total anticholinergic burden in patients with dementia is warranted.

Sign in / Sign up

Export Citation Format

Share Document